Prevention of cervical cancer, cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma in situ, and cervical intraepithelial neoplasia (CIN) grade 1, caused by oncogenic human...

Cervarix is a vaccine against certain types of cancer-causing human papillomavirus (HPV). Cervarix is designed to prevent infection from HPV types 16 and 18, that cause about 70% of cervical cancer cases. [6]

CERVARIX is a vaccine indicated in females from 9 to 45 years of age for the prevention of cervical cancer (squamous cell cancer and adenocarcinoma) by protecting against the following precancerous or dysplastic lesions caused by oncogenic Human Papillomavirus (HPV), types 16 …

2024年8月14日 · Cervarix vaccine is used in girls and young women ages 9 through 25 to prevent cervical cancer caused by certain types of HPV (types 16 and 18). Human papillomavirus (HPV) can cause genital warts, cancer of the cervix, anal cancer, and various cancers of the vulva or vagina. Cervarix is used only in females.

双价人乳头瘤病毒吸附疫苗 （商品名：希瑞适），适用于9~45岁女性，用于预防因高危型人乳头瘤病毒（HPV）16、18型所致疾病。 希瑞适肌肉注射，免疫程序为3剂，于0、1和6月分别接种1剂次，每剂0.5ml。 具体信息详见希瑞适产品说明书。 公示文件. 该网站面向查询有关 中国业务信息的访客。 您可通过点击"选择市场”来访问其他业务市场的网站。 © 2001-2024葛兰素史克集团版权所有。 商标归葛兰素史克集团所有或获授权使用。 北京市朝阳区东四环中路 号楼 层. （京）

Cervarix is a L1 VLP vaccine that includes HPV types 16 and 18, the two major serotypes that are involved with cervical cancer. Thus, the vaccine has been developed to protect against infection from the two major cancer-causing types of HPV; HPV16 and 18, which together are responsible for approximately 70% of all cervical cancers (de Villiers ...

CERVARIX is a vaccine indicated for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18: cervical cancer,

本品适用于预防因高危型人乳头瘤病毒（HPV）16、18型所致下列疾病： •宫颈癌. •2级、3级宫颈上皮内瘤样病变（CIN2/3）和原位腺癌（AIS） •1级宫颈上皮内瘤样病变（CIN1） 【规格】 0.5ml/支（含HPV-16 L1蛋白和HPV-18 L1蛋白各20μg）。 【免疫程序和剂量】 (1)本品肌肉注射，首选接种部位为上臂三角肌。 (2)本品推荐于0、1和6月分别接种1剂次，共接种3剂，每剂0.5ml。 根据本品境外研究数据，第2剂可在第1剂后1～2.5个月之间接种，第3剂可在第1剂 …

Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types.

Cervarix has been shown to have high efficacy against disease associated with both HPV-16 and HPV-18. Its antibody response profile allows for optimism regarding the duration of immunity. The fact that it is a virus-like particle, rather than a live-virus vaccine, is reassuring regarding safety, as …